메뉴 건너뛰기




Volumn 66, Issue 4, 2010, Pages 737-743

Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors

Author keywords

Neuroblastoma; Pharmacokinetics; Tubulin binding agent

Indexed keywords

DRUG METABOLITE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; GLUCURONIDE; SULFATE; SULFONAMIDE;

EID: 77955913113     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1218-z     Document Type: Article
Times cited : (18)

References (10)
  • 1
    • 0031793404 scopus 로고    scopus 로고
    • Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines
    • Iwamoto Y, Nishio K, Fukumoto H, Yoshimatsu K, Yamakido M, Saijo N (1998) Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines. Jpn J Cancer Res 89 (9):954-962
    • (1998) Jpn. J. Cancer Res. , vol.89 , Issue.9 , pp. 954-962
    • Iwamoto, Y.1    Nishio, K.2    Fukumoto, H.3    Yoshimatsu, K.4    Yamakido, M.5    Saijo, N.6
  • 2
    • 0030756156 scopus 로고    scopus 로고
    • Mechanism of action of E7010, an orally active sulfonamide antitumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin
    • Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K (1997) Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 57 (15):3208-3213
    • (1997) Cancer Res. , vol.57 , Issue.15 , pp. 3208-3213
    • Yoshimatsu, K.1    Yamaguchi, A.2    Yoshino, H.3    Koyanagi, N.4    Kitoh, K.5
  • 3
    • 39749199128 scopus 로고    scopus 로고
    • A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
    • Fox E, Maris JM, Widemann BC et al (2008) A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 14 (4):1111-1115
    • (2008) Clin. Cancer Res. , vol.14 , Issue.4 , pp. 1111-1115
    • Fox, E.1    Maris, J.M.2    Widemann, B.C.3
  • 4
    • 33748372759 scopus 로고    scopus 로고
    • A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
    • Fox E, Maris JM, Widemann BC et al (2006) A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 12 (16):4882-4887
    • (2006) Clin. Cancer Res. , vol.12 , Issue.16 , pp. 4882-4887
    • Fox, E.1    Maris, J.M.2    Widemann, B.C.3
  • 5
    • 33646741205 scopus 로고    scopus 로고
    • The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase 1 study
    • Hande KR, Hagey A, Berlin J et al (2006) The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 12 (9):2834-2840
    • (2006) Clin. Cancer Res. , vol.12 , Issue.9 , pp. 2834-2840
    • Hande, K.R.1    Hagey, A.2    Berlin, J.3
  • 6
    • 25144483821 scopus 로고    scopus 로고
    • Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
    • Yee KW, Hagey A, Verstovsek S et al (2005) Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11 (18):6615-6624
    • (2005) Clin. Cancer Res. , vol.11 , Issue.18 , pp. 6615-6624
    • Yee, K.W.1    Hagey, A.2    Verstovsek, S.3
  • 7
    • 39749128674 scopus 로고    scopus 로고
    • In vitro cytotoxicity of ABT-751, a novel tubulin inhibitor, in pediatric solid tumor cell lines
    • Abstr #4351
    • Meany H, Fox E, Hagey AE, Balis FM (2006) In vitro cytotoxicity of ABT-751, a novel tubulin inhibitor, in pediatric solid tumor cell lines. Proc Am Assoc Cancer Res 47:1021 (Abstr #4351)
    • (2006) Proc. Am. Assoc. Cancer Res. , vol.47 , pp. 1021
    • Meany, H.1    Fox, E.2    Hagey, A.E.3    Balis, F.M.4
  • 8
    • 34250618323 scopus 로고    scopus 로고
    • Evaluation of ABT-751 against childhood cancer models in vivo
    • Morton CL, Favours EG, Mercer KS et al (2007) Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 25 (4):285-295
    • (2007) Invest. New Drugs , vol.25 , Issue.4 , pp. 285-295
    • Morton, C.L.1    Favours, E.G.2    Mercer, K.S.3
  • 9
    • 29244488841 scopus 로고    scopus 로고
    • Phase I trial of oral ABT-751 in pediatric patients: Preliminary evidence of activity in neuroblastoma (NBL)
    • June 1, 16S, Part 1 of 2: Abstr # 8527
    • Fox E, Adamson PC, Hagey A, et al (2005) Phase I trial of oral ABT-751 in pediatric patients: preliminary evidence of activity in neuroblastoma (NBL). J Clin Oncol. ASCO Ann Meeting Proc 2005;23(June 1 Suppl) (16S, Part 1 of 2: Abstr # 8527)
    • (2005) J. Clin. Oncol. ASCO Ann. Meeting Proc. 2005 , vol.23 , Issue.SUPPL.
    • Fox, E.1    Adamson, P.C.2    Hagey, A.3
  • 10
    • 33747808956 scopus 로고    scopus 로고
    • Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies
    • Rudek MA, Zhao M, He P, Messersmith WA, Baker SD (2006) Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. J Pharm Biomed Anal 42 (2):253-260
    • (2006) J. Pharm. Biomed. Anal. , vol.42 , Issue.2 , pp. 253-260
    • Rudek, M.A.1    Zhao, M.2    He, P.3    Messersmith, W.A.4    Baker, S.D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.